Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03435081 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03435081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03435081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 20, 2018
Completion date
August 16, 2021
Enrollment
440 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis